Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience

De Giorgi, U; Demirer, TANER; Wandt, H; Taverna, C; Siegert, W; Bornhauser, M; Kozak, T; Papiani, G; Ballardini, M; Rosti, G

doi:10.1093/annonc/mdi017

Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience

De Giorgi U., Demirer T., Wandt H., Taverna C., Siegert W., Bornhauser M., ...More

ANNALS OF ONCOLOGY, vol.16, no.1, pp.146-151, 2005 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 16 Issue: 1
Publication Date: 2005
Doi Number: 10.1093/annonc/mdi017
Journal Name: ANNALS OF ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.146-151
Keywords: EBMT, extragonadal, high-dose chemotherapy, non-seminomatous germ cell tumor, second-line chemotherapy, SALVAGE CHEMOTHERAPY, PROGNOSTIC VARIABLES, CISPLATIN
Ankara University Affiliated: Yes

Abstract

Background: Results of second-line chemotherapy in patients with extragonadal non-seminomatous germ cell tumor (NSGCT) appear inferior to results in testicular NSGCT. Patients with retroperitoneal NSGCT achieve a comparable long-term survival rate of 30%, but the salvage rates of patients with mediastinal primary are less than 10%. We conducted a retrospective analysis on patients with mediastinal and retroperitoneal NSGCT treated with second-line high-dose chemotherapy (HDCT) registered with the European Group for Blood and Marrow Transplantation (EBMT).